Delaware, U.S. – Global hemophilia treatment market is inclined to accumulate substantial returns over the ensuing years owing to the rising cases of genetic abnormalities and increasing prevalence of hemophilia. Hemophilia is a rare bleeding disorder, which causes incessant or prolonged bleeding after an injury or surgery due to delayed blood clotting. Quality care and efficient treatment can help prevent some serious consequences of the disorder.
Request for a sample copy of this report @ https://www.gminsights.com/request-sample/detail/2772
The CDC recommends hemophilia patients to visit a Hemophilia Treatment Center, to seek optimal care and the necessary health education for staying healthy. Increasing deployment of HTCs across the world will positively impact hemophilia treatment market size.
The increasing pervasiveness of hemophiliac cases is the primary growth propeller for hemophilia treatment market. Numbers by the National Hemophilia Foundation suggest that the condition affects over 400,000 people globally and around 75% of affected individuals across the world still have insufficient access to effective treatments. There is currently no cure for hemophilia but there are several treatments that require infusion of drugs made from human plasma or via recombinant biotechnology.
Based on hemophilia type, hemophilia treatment industry is segmented into hemophilia A and hemophilia B. Hemophilia A is inherited as an X-linked recessive trait, which means males are more susceptible to the condition. According to the US Centers for Disease Control and Prevention, 1 in every 5,000 live male births is affected by hemophilia A and around 400 children are born with the condition each year.
Increasing awareness about the type’s severity, symptoms, and treatment will encourage more patients to seek medications, thereby driving hemophilia treatment market growth. In fact, hemophilia A treatment industry size is expected to grow at a CAGR of 5.3% over 2019-2025.
Hemophilia B treatment market is poised to garner substantial growth over the coming years. Patients suffering from hemophilia B bleed for a longer period depending on the proportion of FIX (factor IX) in the plasma, which is the straw-colored fluid part of the blood. Normal plasma levels of FIX are 50% to 150%. People with mild hemophilia carry 6% to 49% of FIX in the blood, people with moderate hemophilia B have 1% to 5%, and people with severe hemophilia have less than 1%.
The demand for advanced treatments created from recombinant biotechnology capable of treating the defective or missing FIX would result in considerable growth of hemophilia B treatment market. The rising requirement of platelets for the treatment of hemophilia will also augment the expansion of platelet and plasma market share. In fact, driven by the rising demand for plasma-derived coagulation factor concentrates in order to overcome the coagulation factor deficiency and avoid excess bleeding in hemophilia patients, plasma-derived factor concentrates based hemophilia treatment market size was worth $1,183.7 million in 2018.
Major industry players have executed several growth strategies such as collaborations, new launches, and mergers to reinforce their position in the global hemophilia treatment market. In 2017, patients with hemophilia A received a more long-lasting option with Roche’s Hemlibra. The drug received approval from Health Canada for hemophilia A patients deprived of factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce its frequency. Increasing demand for Roche’s Hemlibra and similar medications among hemophilia A patients would escalate hemophilia treatment industry share.
Roche has also backed initiatives to help hemophilia patients in emerging economies, where people still have insufficient access to hemophilia drugs. It joined forces with other companies including Sobi, CSL Behring, Grifols, and Sanofi’s Bioverativ to make contributions to the World Hemophilia Federation Humanitarian Aid Program. 16,000 patients across 60 countries benefitted from the program in the year 2017. Such collaborations between non-profit organizations and industry players will help spread awareness and expand hemophilia treatment industry share.
Development of advanced treatment technologies such as hemophilia gene therapy is slated to further augment market growth in the succeeding years. Biotechnology companies have been particularly proactive in this regard, working on investigational gene therapies for patients with severe hemophilia A. Successful execution and approval of hemophilia gene therapy will have a substantial effect on hemophilia treatment market size in the future.
Request for Customization @ https://www.gminsights.com/roc/2772
Although hemophilia gene therapy would take years to come into play, patients are still on a look-out for longer-acting drugs. Newer treatment options, even those that need to be administered once-weekly treatment will turn out to be a huge boon for patients. Moreover, efforts to improve accessibility in developing and economically backward nations will further expand hemophilia treatment industry share. According to a research report by Global Market Insights, Inc., hemophilia treatment market size is estimated to be worth more than USD 14 billion by 2025.